Chronopharmacologic Cancer Treatment with an Angiogenic Vessel-Targeted Liposomal Drug

Shimizu, Kosuke; Sawazaki, Yasuharu; Tanaka, Toshiki; Asai, Tomohiro; Oku, Naoto

doi:10.1248/bpb.31.95

Cited by 17 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the anti‐tumor efficacy of the anti‐angiogenic agent SU1498 (a VEGFR‐2 tyrosine kinase inhibitor) was enhanced when it was administered during the early light phase rather than during the early dark phase in mice 78 . These findings corroborate other studies where decreased efficacy and increased side effects are reported when anti‐angiogenic therapy is delivered at night 81 . The increased sensitivity to anti‐angiogenic therapy during the light phase may be at least partly attributed to increased VEGF‐A levels during the light phase, suggesting that circadian variations in VEGF‐A production affect the efficacy of anti‐angiogenic therapy 78 .…”

Section: Exploiting the Circadian Clock To Personalised Anti‐angiogen...supporting

confidence: 89%

“…78 These findings corroborate other studies where decreased efficacy and increased side effects are reported when anti‐angiogenic therapy is delivered at night. 81 The increased sensitivity to anti‐angiogenic therapy during the light phase may be at least partly attributed to increased VEGF‐A levels during the light phase, suggesting that circadian variations in VEGF‐A production affect the efficacy of anti‐angiogenic therapy. 78 Since mice are nocturnal animals, VEGF‐A levels peaking during the light phase correspond to the increase in VEGF‐A levels in humans or zebrafish, which are diurnal, during the night.…”

Section: Exploiting the Circadian Clock To Personalised Anti‐angiogen...mentioning

confidence: 99%

See 1 more Smart Citation

Circadian rhythms in psoriasis and the potential of chronotherapy in psoriasis management

Luengas‐Martinez

Paus

Iqbal

et al. 2022

Experimental Dermatology

View full text Add to dashboard Cite

The physiology and pathology of the skin are influenced by daily oscillations driven by a master clock located in the brain, and peripheral clocks in individual cells. The pathogenesis of psoriasis is circadian‐rhythmic, with flares of disease and symptoms such as itch typically being worse in the evening/night‐time. Patients with psoriasis have changes in circadian oscillations of blood pressure and heart rate, supporting wider circadian disruption. In addition, shift work, a circadian misalignment challenge, is associated with psoriasis. These features may be due to underlying circadian control of key effector elements known to be relevant in psoriasis such as cell cycle, proliferation, apoptosis and inflammation. Indeed, peripheral clock pathology may lead to hyperproliferation of keratinocytes in the basal layers, insufficient apoptosis of differentiating keratinocytes in psoriatic epidermis, dysregulation of skin‐resident and migratory immune cells and modulation of angiogenesis through circadian oscillation of vascular endothelial growth factor A (VEGF‐A) in epidermal keratinocytes. Chronotherapeutic effects of topical steroids and topical vitamin D analogues have been reported, suggesting that knowledge of circadian phase may improve the efficacy, and therapeutic index of treatments for psoriasis. In this viewpoint essay, we review the current literature on circadian disruption in psoriasis. We explore the hypothesis that psoriasis is circadian‐driven. We also suggest that investigation of the circadian components specific to psoriasis and that the in vitro investigation of circadian regulation of psoriasis will contribute to the development of a novel chronotherapeutic treatment strategy for personalised psoriasis management. We also propose that circadian oscillations of VEGF‐A offer an opportunity to enhance the efficacy and tolerability of a novel anti‐VEGF‐A therapeutic approach, through the timed delivery of anti‐VEGF‐A drugs.

show abstract

Section: Exploiting the Circadian Clock To Personalised Anti‐angiogen...supporting

confidence: 89%

Section: Exploiting the Circadian Clock To Personalised Anti‐angiogen...mentioning

confidence: 99%

Circadian rhythms in psoriasis and the potential of chronotherapy in psoriasis management

Luengas‐Martinez

Paus

Iqbal

et al. 2022

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…APRPG peptide has high affinity to angiogenic sites. 108 Three times of injection of Colon 26 NL-17 tumor-bearing mice with APRPG-LipADM preparation at four different time points induced altered tumor growth suppression depending on the dosing time. More potent tumor growth suppression was observed in the early dark phase than the late dark phase.…”

Section: Chrono-drug Delivery Systemmentioning

confidence: 99%

Molecular Basis of Chronopharmaceutics

Ohdo

Koyanagi

Matsumoto

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Angiogenesis, the formation of new blood vessels, is an essential condition for the development of tumors with a diameter greater than 1-2 mm and also for their metastatic dissemination. Therefore, antiangiogenesis would also be an efficient and prospective method in the growth inhibition and metastasis of tumors [17]. Surgery is the mainstay of therapy, but chemotherapeutic method is the most important measure after the operation, which may enhance survival rate.…”

Section: Introductionmentioning

confidence: 99%

Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells

Chen¹,

Peng²,

Ouyang³

et al. 2008

Melanoma Research

View full text Add to dashboard Cite

Ginsenoside Rg3 is an effective chemical component extracted from the red Panix. The experiment demonstrated that it might effectively inhibit proliferation and metastasis of tumor cells. The exact molecular mechanism of Rg3 remains unclear so far. To further explore the antitumor function of Rg3, we investigated the in-vitro and in-vivo activity of Rg3 in the treatment of B16 melanoma cells, derived from C57BL/6 mouse, capable of forming tumor colonies in the lungs following intravenous injection. Cell proliferation was measured by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide assay. Morphological changes of cells were observed by staining with Giesma and Hoechst 33258. Cell cycle and apoptosis rate were analyzed by flow cytometry. The expression of caspase-3 and bcl-2 in cells was detected by immunocytochemistry and western blot analysis. We found that Rg3 could inhibit cell proliferation, regulate cell cycle, and induce cell apoptosis in vitro. B16 melanoma-bearing mice were used to evaluate in vivo the antitumor activity of Rg3. Mice that were injected with Rg3 showed significant inhibition of the tumor metastasis with lighter lung weight, lower density of microvessels, fewer metastasis nodules, and longer survival time than those in the control group (P<0.001). In conclusion, the results reveal that antitumor metastasis of Rg3 is also associated with inducing apoptosis, regulating cell cycle, and blocking angiogenesis in addition to inhibiting proliferation. This research might supply valuable data for chemotherapy with Rg3 in melanoma. Rg3 would turn out to be an anticancer drug with promising prospects.

show abstract

Chronopharmacologic Cancer Treatment with an Angiogenic Vessel-Targeted Liposomal Drug

Cited by 17 publications

References 30 publications

Circadian rhythms in psoriasis and the potential of chronotherapy in psoriasis management

Circadian rhythms in psoriasis and the potential of chronotherapy in psoriasis management

Molecular Basis of Chronopharmaceutics

Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells

Contact Info

Product

Resources

About